We are live on ! Find out more
AVLSA

Atlas Venture Life Science Advisors Portfolio holdings

AUM $881M
1-Year Est. Return 160.77%
This Fund
S&P 500
This Quarter Est. Return
+37.56%
1 Year Est. Return
+160.77%
3 Year Est. Return
+483.58%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$906M
AUM Growth
+$308M
Cap. Flow
+$153M
Cap. Flow %
16.86%
Top 10 Hldgs %
96.53%
Holding
17
New
1
Increased
–
Reduced
4
Closed
–

Top Buys

Rank Stock Value
1
THRD
Third Harmonic Bio
THRD
+$197M

Top Sells

Rank Stock Value
1
AKRO
Akero Therapeutics
AKRO
+$18.9M
2
DAWN
Day One Biopharmaceuticals
DAWN
+$17M
3
JBIO
Jade Biosciences
JBIO
+$5.92M
4
REPL icon
Replimune Group
REPL
+$1.93M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
THRD
1
DELISTED
Third Harmonic Bio
THRD
$207M 22.84%
+10,907,859
New +$197M
DAWN
2
DELISTED
Day One Biopharmaceuticals
DAWN
$164M 18.06%
8,169,171
-799,134
-9% -$17M
KYMR icon
3
Kymera Therapeutics
KYMR
$9.85B
$150M 16.52%
6,875,698
– –
DYN icon
4
Dyne Therapeutics
DYN
$3.37B
$113M 12.52%
8,934,902
– –
REPL icon
5
Replimune Group
REPL
$1.21B
$53.7M 5.92%
3,108,300
-101,327
-3% -$1.93M
VIGL
6
DELISTED
Vigil Neuroscience
VIGL
$53.1M 5.86%
5,836,874
– –
GBIO
7
DELISTED
Generation Bio
GBIO
$44M 4.85%
827,888
– –
JBIO
8
Jade Biosciences
JBIO
$1.09B
$38.6M 4.26%
66,512
-8,868
-12% -$5.92M
AKRO
9
DELISTED
Akero Therapeutics
AKRO
$33.9M 3.74%
994,251
-1,238,000
-55% -$18.9M
IMA
10
ImageneBio Inc
IMA
$57M
$17.8M 1.97%
418,182
– –
IRON icon
11
Disc Medicine
IRON
$2.66B
$8.62M 0.95%
175,146
– –
XLO icon
12
Xilio Therapeutics
XLO
$59.5M
$8.03M 0.89%
197,096
– –
DNTH icon
13
Dianthus Therapeutics
DNTH
$5.66B
$4.9M 0.54%
217,284
– –
FSTX
14
DELISTED
F-star Therapeutics, Inc. Common Stock
FSTX
$3.07M 0.34%
599,524
– –
TECX
15
Tectonic Therapeutic
TECX
$532M
$2.9M 0.32%
376,739
– –
SPRO icon
16
Spero Therapeutics
SPRO
$65.2M
$2.06M 0.23%
1,031,160
– –
VRDN icon
17
Viridian Therapeutics
VRDN
$2.48B
$1.85M 0.2%
90,072
– –

Similar funds

AAA
Adams Asset Advisors Dallas, Texas $882M AUM 42% 1-Year Est. Return
FSCM
Front Street Capital Management Missoula, Montana $881M AUM 86.5% 1-Year Est. Return
CCA
Canyon Capital Advisors Dallas, Texas $882M AUM 62.77% 1-Year Est. Return
TAM
TCP Asset Management Columbus, Ohio $882M AUM 21.79% 1-Year Est. Return
FFG
Fiduciary Financial Group San Rafael, California $882M AUM 23.98% 1-Year Est. Return
MWA
Meridian Wealth Advisors Austin, Texas $880M AUM 30.15% 1-Year Est. Return
1IA
1834 Investment Advisors Milwaukee, Wisconsin $883M AUM 23.82% 1-Year Est. Return
EPAM
Euro Pacific Asset Management Dorado, Puerto Rico $880M AUM 44.18% 1-Year Est. Return

Atlas Venture Life Science Advisors's Q3 2022 Portfolio in Review

As of Q3 2022, Atlas Venture Life Science Advisors held 17 positions worth $906M, up 51% from $598M the previous quarter. Its ten largest holdings account for 97% of the portfolio.

Atlas Venture Life Science Advisors deployed $153M of net new capital in Q3 2022, opening 1 new position. Its largest new stake was Third Harmonic Bio: 10,907,859 shares worth $207M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

On the sell side, the largest reduction was Akero Therapeutics, an estimated $18.9M trimmed.

  • Atlas Venture Life Science Advisors's largest Q3 2022 buy was Third Harmonic Bio: 10,907,859 shares worth $207M.
  • Atlas Venture Life Science Advisors's biggest Q3 2022 reduction was Akero Therapeutics, cutting an estimated $18.9M.
  • Atlas Venture Life Science Advisors's ten largest holdings make up 97% of its $906M portfolio in Q3 2022.
  • Atlas Venture Life Science Advisors opened 1 new position and closed 0 in Q3 2022.
  • Atlas Venture Life Science Advisors's portfolio value rose 51% quarter-over-quarter to $906M.

Based on Atlas Venture Life Science Advisors's 13F filing for Q3 2022, filed 9 Nov 2022.